Baseline and interval laboratory monitoring should include: fasting glucose and HbA1c (tirzepatide can cause hypoglycemia in non-diabetic subjects if caloric intake drops too low), lipase and amylase (pancreatitis risk with GLP-1 agonists), liver function tests (AST, ALT, bilirubin), and thyroid panel (TSH, free T3, free T4)
One looked at the effect of BPC-157 on bladder pain (12 people) and the other looked at knee pain (16 people)
This is different from the lyophilized (freeze-dried) powder, which is stable at frozen temperatures
AOD-9604 is currently sold for research purposes only and lacks regulatory approval from any major health authority worldwide
That may not seem like much, but it's about 500 to 800 times more than the recommended daily intake of 2.4 micrograms